Early detection of lung cancer through programmatic management of pulmonary nodules in the Mississippi Delta.

Authors

Matthew Smeltzer

Matthew Smeltzer

University of Memphis, School of Public Health, Memphis, TN

Matthew Smeltzer, Wei Liao, Nicholas R Faris, Carrie Fehnel, Jordan Goss, Catherine J Shepherd, Talat Qureshi, Anberitha T Matthews, Meredith Ray, Raymond U. Osarogiagbon

Organizations

University of Memphis, School of Public Health, Memphis, TN, Baptist Cancer Center, Memphis, TN, Baptist Memorial Healthcare System, Memphis, TN, Baptist Cancer Center, Multidisciplinary Thoracic Oncology Department, Memphis, TN, Thoracic Oncology Research Group, Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, TN, Memphis, TN, Baptist Cancer Center, Multidisciplinary Thoracic Oncology Program, Memphis, TN

Research Funding

Other Foundation
Baptist Memorial Health Care Foundation for initial funding support: Grant # 15BD03

Background: Lung cancer (LC) causes the most cancer deaths in the US, but early detection improves outcomes. Uptake of Low-Dose CT screening (LDCT) has been low, contributing to race-based disparities. Programmatic management of incidentally detected pulmonary nodules (PN) provides a complementary avenue for early detection which could address disparities. In our PN cohort, Detecting Early LC in the Mississippi Delta (DELUGE), we provide broad access to early detection across a region fraught with geographic, socioeconomic, and race-based disparities. However, many detected PN will not result in LC. After successful implementation at the program level, we seek to evaluate individual-level factors important for early-detection. We evaluated how individuals with small PN identified in DELUGE differ between those who were and were not diagnosed with LC. Methods: DELUGE is a prospective cohort study where we systematically manage incidentally detected PN with trained navigators and evidence-based risk stratification. We constructed DELUGE in a community-based healthcare system across the mid-south with some of the highest per-capita LC incidence and mortality rates in the US. We evaluated all PN ≤30mm in DELUGE from 2015-2022. We compared clinical and demographic characteristics between individuals who were or were not diagnosed with LC within 24 months. Primary analysis used logistic regression, reporting odds ratios (OR) with 95% confidence intervals. Results: From 2015-2022, 17,945 individuals with PN ≤30 mm (71% of the total cohort of 25,339) were identified and enrolled in DELUGE. They had median age of 65 years, were 56% female, and 27% Black / 69% White. 853 (4.8%) patients were diagnosed with LC within two years. PN size significantly predicted LC diagnosis. For every 1 mm increase in nodule size the odds of LC increased by 15% (OR: 1.15 [1.14-1.16]); PN in an upper lobe (OR: 2.0 [1.7-2.2]) and those with cavitation also increased the odds of LC (OR: 2.9[1.9-4.2]). Sex, rural/urban residence, and number of PN were not associated with LC. The most predictive individual level characteristics were age, prior cancer history (OR: 1.3 [1.1-1.5], family cancer history (OR: 1.7 [1.5-2.0], COPD (OR: 3.3 [2.9-3.8]), and smoking history (OR: 6.6 [5.3-8.4]). In the multiple variable model, the most significant associations with LC diagnosis included PN size, age, insurance, family cancer history, COPD, and smoking history (all p<0.0001). This model could provide estimated sensitivity 0.81 and specificity 0.81 for predicting LC (AUC= 0.88). Conclusions: Factors measurable at baseline have predictive ability, and predictive modeling may be useful in management of small PN. More focused follow-up could improve programmatic efficiency, targeting the alleviation of geographic, socioeconomic, and race-based health disparities in this high poverty region of the US.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Quality Care Symposium

Session Type

Poster Session

Session Title

Poster Session B

Track

Health Care Access, Equity, and Disparities,Technology and Innovation in Quality of Care,Palliative and Supportive Care

Sub Track

Access to Timely Detection and Referral

Citation

JCO Oncol Pract 19, 2023 (suppl 11; abstr 126)

DOI

10.1200/OP.2023.19.11_suppl.126

Abstract #

126

Poster Bd #

C3

Abstract Disclosures

Similar Abstracts

Abstract

2022 ASCO Annual Meeting

Incidental pulmonary nodules, lung cancer screening, and lung cancer in the Medicare population.

First Author: Raymond U. Osarogiagbon

Abstract

2023 ASCO Quality Care Symposium

Rural-urban disparities in lung cancer-related mortality in the United States.

First Author: Shiva Jashwanth Gaddam